13 results on '"Karsten, T M"'
Search Results
2. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3):study protocol for a multicenter randomized controlled trial
- Author
-
van Dam, J. L., Verkolf, E. M.M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A.A., Busch, O. R., van Driel, L. M.J.W., van Eijck, C. H.J., Feshtali, S., Ghorbani, P., de Groot, D. J.A., de Groot, J. W.B., Haberkorn, B. C.M., de Hingh, I. H., van der Holt, B., Karsten, T. M., van der Kolk, M. B., Labori, K. J., Liem, M. S.L., Loosveld, O. J.L., Molenaar, I. Q., Polée, M. B., van Santvoort, H. C., de Vos-Geelen, J., Wumkes, M. L., van Tienhoven, G., Homs, M. Y.V., Besselink, M. G., Wilmink, J. W., Groot Koerkamp, B., van Dam, J. L., Verkolf, E. M.M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A.A., Busch, O. R., van Driel, L. M.J.W., van Eijck, C. H.J., Feshtali, S., Ghorbani, P., de Groot, D. J.A., de Groot, J. W.B., Haberkorn, B. C.M., de Hingh, I. H., van der Holt, B., Karsten, T. M., van der Kolk, M. B., Labori, K. J., Liem, M. S.L., Loosveld, O. J.L., Molenaar, I. Q., Polée, M. B., van Santvoort, H. C., de Vos-Geelen, J., Wumkes, M. L., van Tienhoven, G., Homs, M. Y.V., Besselink, M. G., Wilmink, J. W., and Groot Koerkamp, B.
- Abstract
BACKGROUND: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant chemotherapy is that only half of patients actually receive adjuvant treatment. Neoadjuvant chemotherapy, on the other hand, guarantees early systemic treatment and may increase chemotherapy use and thereby improve overall survival. Furthermore, it may prevent futile surgery in patients with rapidly progressive disease. However, some argue that neoadjuvant therapy delays surgery, which could lead to progression towards unresectable disease and thus offset the potential benefits. Comparison of perioperative (i.e., neoadjuvant and adjuvant) with (only) adjuvant administration of mFOLFIRINOX in a randomized controlled trial (RCT) is needed to determine the optimal approach. METHODS: This multicenter, phase 3, RCT will include 378 patients with resectable pancreatic ductal adenocarcinoma with a WHO performance status of 0 or 1. Patients are recruited from 20 Dutch centers and three centers in Norway and Sweden. Resectable pancreatic cancer is defined as no arterial contact and ≤ 90 degrees venous contact. Patients in the intervention arm are scheduled for 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (2-week cycle of oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2 at day 1, followed by 46 h continuous infusion of 5-fluorouracil 2400 g/m2). Patients in the comparator arm start with surgery followed by 12 cycles of adjuvant mFOLFIRINOX. The primary outcome is overall survival by intention-to-treat. Secondary outcomes include progression-free survival, resection rate, quality of life, adverse events, and surgical complications. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after the inclusion of
- Published
- 2023
3. C-reactive protein (CRP) trajectory as a predictor of anastomotic leakage after rectal cancer resection
- Author
-
Hoek, V. T., Sparreboom, C. L., Wolthuis, A. M., Menon, A. G., Kleinrensink, G. J., D'Hoore, A., Komen, N., Lange, J. F., van Westreenen, H. L., Doornebosch, P. G., Dekker, J. W. T., Daams, F., Lips, D. J., van Grevenstein, W. M. U., Karsten, T. M., Surgery, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, APPEAL II collaborators, Plastic and Reconstructive Surgery and Hand Surgery, Neurosciences, and Erasmus MC other
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Anastomotic Leak ,anastomotic leakage ,Gastroenterology ,C-reactive protein ,Cohort Studies ,COLORECTAL SURGERY ,rectal surgery ,SDG 3 - Good Health and Well-being ,Predictive Value of Tests ,Positive predicative value ,Internal medicine ,INFECTIOUS COMPLICATIONS ,medicine ,Humans ,Prospective Studies ,Science & Technology ,Gastroenterology & Hepatology ,biology ,Receiver operating characteristic ,business.industry ,Rectal Neoplasms ,medicine.disease ,Point of delivery ,C-Reactive Protein ,ROC Curve ,Anastomotic leakage ,RISK-FACTORS ,biology.protein ,Adenocarcinoma ,Surgery ,Human medicine ,business ,Life Sciences & Biomedicine ,Biomarkers ,Cohort study - Abstract
AIM: This study aimed to identify whether CRP-trajectory measurement, including increase in CRP-level of 50 mg/l per day, is an accurate predictor of anastomotic leakage (AL) in patients undergoing resection for rectal cancer. METHODS: A prospective multicentre database was used. CRP was recorded on the first three postoperative days. Sensitivity, specificity, positive and negative predictive values, and area under the receiver operator characteristic (ROC) curve were used to analyse performances of CRP-trajectory measurements between postoperative day (POD) 1-2, 2-3, 1-3 and between any two days. RESULTS: A total of 271 patients were included in the study. AL was observed in 12.5% (34/271). Increase in CRP-level of 50 mg/l between POD 1-2 had a negative predictive value of 0.92, specificity of 0.71 and sensitivity of 0.57. Changes in CRP-levels between POD 2-3 were associated with a negative predictive value, specificity and sensitivity of 0.89, 0.93 and 0.26, respectively. Changes in CRP-levels between POD 1-3 showed a negative predictive value of 0.94, specificity of 0.76 and sensitivity of 0.65. In addition, 50 mg/l changes between any two days showed a negative predictive value of 0.92, specificity of 0.66 and sensitivity of 0.62. The area under the ROC curve for all CRP-trajectory measurements ranged from 0.593-0.700. CONCLUSION: The present study showed that CRP-trajectory between postoperative days lacks predictive value to singularly rule out AL. Early and safe discharge in patients undergoing rectal surgery for adenocarcinoma cannot be guaranteed based on this parameter. High negative predictive values are mainly caused by the relatively low prevalence of AL. ispartof: COLORECTAL DISEASE vol:24 issue:2 pages:220-227 ispartof: location:England status: published
- Published
- 2022
4. C-reactive protein (CRP) trajectory as a predictor of anastomotic leakage after rectal cancer resection: A multicentre cohort study
- Author
-
Hoek, V. T., Sparreboom, C. L., Wolthuis, A. M., Menon, A. G., Kleinrensink, G. J., D'Hoore, A., Komen, N., Lange, J. F., van Westreenen, H. L., Doornebosch, P. G., Dekker, J. W. T., Daams, F., Lips, D. J., van Grevenstein, W. M. U., Karsten, T. M., Hoek, V. T., Sparreboom, C. L., Wolthuis, A. M., Menon, A. G., Kleinrensink, G. J., D'Hoore, A., Komen, N., Lange, J. F., van Westreenen, H. L., Doornebosch, P. G., Dekker, J. W. T., Daams, F., Lips, D. J., van Grevenstein, W. M. U., and Karsten, T. M.
- Abstract
Aim: This study aimed to identify whether CRP-trajectory measurement, including increase in CRP-level of 50 mg/l per day, is an accurate predictor of anastomotic leakage (AL) in patients undergoing resection for rectal cancer. Methods: A prospective multicentre database was used. CRP was recorded on the first three postoperative days. Sensitivity, specificity, positive and negative predictive values, and area under the receiver operator characteristic (ROC) curve were used to analyse performances of CRP-trajectory measurements between postoperative day (POD) 1–2, 2–3, 1–3 and between any two days. Results: A total of 271 patients were included in the study. AL was observed in 12.5% (34/271). Increase in CRP-level of 50 mg/l between POD 1–2 had a negative predictive value of 0.92, specificity of 0.71 and sensitivity of 0.57. Changes in CRP-levels between POD 2–3 were associated with a negative predictive value, specificity and sensitivity of 0.89, 0.93 and 0.26, respectively. Changes in CRP-levels between POD 1–3 showed a negative predictive value of 0.94, specificity of 0.76 and sensitivity of 0.65. In addition, 50 mg/l changes between any two days showed a negative predictive value of 0.92, specificity of 0.66 and sensitivity of 0.62. The area under the ROC curve for all CRP-trajectory measurements ranged from 0.593–0.700. Conclusion: The present study showed that CRP-trajectory between postoperative days lacks predictive value to singularly rule out AL. Early and safe discharge in patients undergoing rectal surgery for adenocarcinoma cannot be guaranteed based on this parameter. High negative predictive values are mainly caused by the relatively low prevalence of AL.
- Published
- 2022
5. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial):study protocol for a nationwide multicenter randomized controlled trial
- Author
-
Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., De Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., Koerkamp, B. Groot, Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., De Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., and Koerkamp, B. Groot
- Abstract
BackgroundNeoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.MethodsThis nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and <= 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as <= 90 degrees arterial and <= 270 degrees venous involvement without occlusion. Patients receive 8cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36Gy in 15 fractions) during the second cycle, followed by surgery and 4cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients as
- Published
- 2021
6. Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy:a multicentre cohort study and meta-analysis
- Author
-
Groen, J., Smits, F. J., Koole, D., Besselink, M. G., Busch, O. R., den Dulk, M., van Eijck, C. H. J., Koerkamp, B. Groot, van der Harst, E., de Hingh, I. H., Karsten, T. M., de Meijer, V. E., Pranger, B. K., Molenaar, I. Q., Bonsing, B. A., van Santvoort, H. C., Mieog, J. S. D., Groen, J., Smits, F. J., Koole, D., Besselink, M. G., Busch, O. R., den Dulk, M., van Eijck, C. H. J., Koerkamp, B. Groot, van der Harst, E., de Hingh, I. H., Karsten, T. M., de Meijer, V. E., Pranger, B. K., Molenaar, I. Q., Bonsing, B. A., van Santvoort, H. C., and Mieog, J. S. D.
- Abstract
BACKGROUND: Despite the fact that primary percutaneous catheter drainage has become standard practice, some patients with pancreatic fistula after pancreatoduodenectomy ultimately undergo a relaparotomy. The aim of this study was to compare completion pancreatectomy with a pancreas-preserving procedure in patients undergoing relaparotomy for pancreatic fistula after pancreatoduodenectomy. METHODS: This retrospective cohort study of nine institutions included patients who underwent relaparotomy for pancreatic fistula after pancreatoduodenectomy from 2005-2018. Furthermore, a systematic review and meta-analysis were performed according to the PRISMA guidelines. RESULTS: From 4877 patients undergoing pancreatoduodenectomy, 786 (16 per cent) developed a pancreatic fistula grade B/C and 162 (3 per cent) underwent a relaparotomy for pancreatic fistula. Of these patients, 36 (22 per cent) underwent a completion pancreatectomy and 126 (78 per cent) a pancreas-preserving procedure. Mortality was higher after completion pancreatectomy (20 (56 per cent) versus 40 patients (32 per cent); P = 0.009), which remained after adjusting for sex, age, BMI, ASA score, previous reintervention, and organ failure in the 24 h before relaparotomy (adjusted odds ratio 2.55, 95 per cent c.i. 1.07 to 6.08). The proportion of additional reinterventions was not different between groups (23 (64 per cent) versus 84 patients (67 per cent); P = 0.756). The meta-analysis including 33 studies evaluating 745 patients, confirmed the association between completion pancreatectomy and mortality (Mantel-Haenszel random-effects model: odds ratio 1.99, 95 per cent c.i. 1.03 to 3.84). CONCLUSION: Based on the current data, a pancreas-preserving procedure seems preferable to completion pancreatectomy in patients in whom a relaparotomy is deemed necessary for pancreatic fistula after pancreatoduodenectomy.
- Published
- 2021
7. Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy: a multicentre cohort study and meta-analysis
- Author
-
MS CGO, Heelkunde Opleiding, Cancer, MS HOD, Groen, J., V, Smits, F. J., Koole, D., Besselink, M. G., Busch, O. R., den Dulk, M., van Eijck, C. H. J., Koerkamp, B. Groot, van der Harst, E., de Hingh, I. H., Karsten, T. M., de Meijer, V. E., Pranger, B. K., Molenaar, I. Q., Bonsing, B. A., van Santvoort, H. C., Mieog, J. S. D., MS CGO, Heelkunde Opleiding, Cancer, MS HOD, Groen, J., V, Smits, F. J., Koole, D., Besselink, M. G., Busch, O. R., den Dulk, M., van Eijck, C. H. J., Koerkamp, B. Groot, van der Harst, E., de Hingh, I. H., Karsten, T. M., de Meijer, V. E., Pranger, B. K., Molenaar, I. Q., Bonsing, B. A., van Santvoort, H. C., and Mieog, J. S. D.
- Published
- 2021
8. A multicentre cohort study of serum and peritoneal biomarkers to predict anastomotic leakage after rectal cancer resection
- Author
-
Sparreboom, C L, Komen, N, Rizopoulos, D, Verhaar, A P, Dik, W A, Wu, Z, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Bayon, Y, Peppelenbosch, M P, Wolthuis, A M, D'Hoore, A, Lange, J F, Sparreboom, C L, Komen, N, Rizopoulos, D, Verhaar, A P, Dik, W A, Wu, Z, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Bayon, Y, Peppelenbosch, M P, Wolthuis, A M, D'Hoore, A, and Lange, J F
- Published
- 2020
9. A multicentre cohort study of serum and peritoneal biomarkers to predict anastomotic leakage after rectal cancer resection
- Author
-
MS CGO, Cancer, MS Gynaecologische Oncologie, Sparreboom, C L, Komen, N, Rizopoulos, D, Verhaar, A P, Dik, W A, Wu, Z, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Bayon, Y, Peppelenbosch, M P, Wolthuis, A M, D'Hoore, A, Lange, J F, MS CGO, Cancer, MS Gynaecologische Oncologie, Sparreboom, C L, Komen, N, Rizopoulos, D, Verhaar, A P, Dik, W A, Wu, Z, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Bayon, Y, Peppelenbosch, M P, Wolthuis, A M, D'Hoore, A, and Lange, J F
- Published
- 2020
10. Transanal total mesorectal excision: how are we doing so far?
- Author
-
Verpleegafd Vaatchirurgie D4 Oost, MS CGO, Cancer, Sparreboom, C L, Komen, N, Rizopoulos, D, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Tuynman, J B, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Lange, J F, D'Hoore, A, Wolthuis, A M, Verpleegafd Vaatchirurgie D4 Oost, MS CGO, Cancer, Sparreboom, C L, Komen, N, Rizopoulos, D, van Westreenen, H L, Doornebosch, P G, Dekker, J W T, Menon, A G, Tuynman, J B, Daams, F, Lips, D, van Grevenstein, W M U, Karsten, T M, Lange, J F, D'Hoore, A, and Wolthuis, A M
- Published
- 2019
11. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
- Author
-
Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., de Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y. V., van Tienhoven, G., Besselink, M. G., and Wilmink, J. W.
- Subjects
PANCREATIC cancer ,CHEMORADIOTHERAPY ,PANCREATIC surgery ,QUALITY of life ,NEOADJUVANT chemotherapy ,PROGRESSION-free survival ,CANCER patients - Abstract
Background: Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.Methods: This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and ≤ 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as ≤90 degrees arterial and ≤ 270 degrees venous involvement without occlusion. Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients assuming an accrual period of 3 years and 1.5 years follow-up.Discussion: The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer.Trial Registration: Primary registry and trial identifying number: EudraCT: 2017-002036-17 . Date of registration: March 6, 2018. Secondary identifying numbers: The Netherlands National Trial Register - NL7094 , NL61961.078.17, MEC-2018-004. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. THE EFFECT OF COMMON BILE DUCT OBSTRUCTION ON BACTERIAL TRANSLOCATION FROM BILIARY TRACT TO BLOODSTREAM AND LYMPHATIC SYSTEM.
- Author
-
Karsten, T. M., Gulik, T. v., Spanjaard, L., Bosma, A., Dankert, P., and Gouma, D.
- Published
- 1996
13. HETEROTOPIC AUTOTRANSPLANTATION OF CANINE LIVER SEGMENTS.
- Author
-
Ringers, J., Karsten, T. M., De Wit, L. T., Van Gulik, T. M., and van der Heyde, M. N.
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.